A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen–progestogen treatment

References

• Barrett-Connor E. Hormone replacement therapy. Br Med J 1998;317:457–61
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362: 419–27
   PubMed Web of Science ®Google Scholar
• Preston-Martin S, Pike MC, Ross RK, et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415–21
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton J, McCartney C, etal. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16–23
   PubMed Web of Science ®Google Scholar
• Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1–21
   PubMedGoogle Scholar
• Rymer JM. The effects of tibolone. Gynecol Endocrinol 1998;12:213–20
   PubMed Web of Science ®Google Scholar
• Pasqualini JR, Chetrite GS. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 1999;69:287–92
   PubMed Web of Science ®Google Scholar
• Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351–9
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559–65
   PubMed Web of Science ®Google Scholar
• Franzen S, Zajicek J. Aspiration biopsy in diag-nosis of palpable lesions of the breast. Critical review of 3479 consecutive biopsies. Acta Radiol Ther Phys Biol 1968;7:241–62
   Google Scholar
• Skoog L, Humla S, Isaksson S, et al. Immunocytochemical analysis of receptors for estrogen and progesterone in fine-needle aspirates from human breast carcinomas. Diagn Cytopathol 1990;6:95–8
   PubMed Web of Science ®Google Scholar
• Skoog L, Rutqvist LE, Wilking N. Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 1992;31:139–41
   Google Scholar
• Soderqvist G, Isaksson E, von Schoultz B, et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123–8
   PubMed Web of Science ®Google Scholar
• Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001; 65:163–9
   PubMed Web of Science ®Google Scholar
• Conner P, Skoog L, Soderqvist G. Breast epithe-lial proliferation in postmenopausal women evaluated through fine-needle-aspiration cyto-logy. Climacteric 2001;4:7–12
   Google Scholar
• Conner P, Söderqvist G, Skoog L, etal. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78: 159–65
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717–22
   PubMed Web of Science ®Google Scholar
• Gerdes J, Li L, Schlueter C, et al. Immuno-biochemical and molecular biologic characteriza-tion of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867–73
   PubMed Web of Science ®Google Scholar
• Sodergard R, Bäckström T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradio1-170 to human plasma proteins at body temperature. J Steroid Biochem 1982;187:801–10
   Google Scholar
• Reid SE, Murthy MS, Kaufman M, et al. Endo-crine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996;83:1037–46
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of indi-vidual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713–27
   PubMed Web of Science ®Google Scholar
• Boyd NF, Lockwood GA, Byng JW, et al. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prey 1998; 7:1133–44
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;81: 348–52
   Google Scholar
• Kloosterboer HJ, Schoonen WG, Deckers GH, et al. Effects of progestagens and Org 0D14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311–18
   PubMed Web of Science ®Google Scholar
• Zhou J, Ng S, Adesanya-Famuiya 0, et al. Testosteroneinhibitsestrogen-inducedmammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000; 12:1725–30
   Google Scholar
• Pye JK, Mansel RE, Hughes LE. Clinical experi-ence of drug treatments for mastalgia. Lancet 1985;2:373–7
   Google Scholar
• Dimitrakakis C, Zhou J, Wang J, etal. A physio-logic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10:292–8
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292–9
   PubMed Web of Science ®Google Scholar